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Health services research (HSR) seeks to provide data from real-world studies (unlike the controlled environment of 
randomized clinical trials) that will assist clini-
cians as well as health-care policy makers in 
delivering high-quality care in the most cost-
effective manner. HSR encompasses studies 
that measure and determine predictors of health 
outcomes in the real world, including survival, 
quality of life, and economic impact. Predictors 
of outcome include social factors, insurance/
financing systems, processes of care, health 
technologies, and personal behaviors. Quality 
of life includes subjective well-being, health 
status, and patient preference valuations (e.g., 
utilities). Economic impact in general refers 
to cost of illness. Pharmacoeconomic studies, 
which compare the cost as well as the effective-
ness of one therapeutic intervention with that 
of another, include cost-effectiveness analyses, 
cost–utility analyses, and cost–benefit analyses 
and are an important component of HSR. These 
studies may be performed in the context of pro-
spective trials as well as retrospective analyses 
of databases.
In addition to the “Burden of Skin Disease” 
issue of the JID Symposium Proceedings (March 
2004), recent papers published in the Journal 
have concentrated primarily on quality-of-life 
instrument development and outcomes:
•	VanBeek	M,	Beach	S,	Braslow	L et al. 
(2007) Highlights from the report of the 
working group on “Core Measures of the 
Burden of Skin Diseases.” J Invest Dermatol 
127:2701–6
•	Both	H,	Essink-Bot	ML,	Busschbach	J	et 
al. (2007) Critical review of generic and 
dermatology-specific health-related quality 
of life instruments. J Invest Dermatol 
127:2726–39
•	Nijsten	T,	Meads	DM,	de	Korte	J et al. 
(2007) Cross-cultural inequivalence of 
dermatology-specific health-related quality 
of life instruments in psoriasis patients.  
J Invest Dermatol 127:2315–22
•	Chren	MM,	Sahay	AP,	Bertenthal	DS 
et al. (2007) Quality-of-life outcomes 
of treatments for cutaneous basal cell 
carcinoma and squamous cell carcinoma.  
J Invest Dermatol 127:1351–7
•	Nijsten	TE,	Sampogna	F,	Chren	MM et al. 
(2006) Testing and reducing skindex-29 
using Rasch analysis: Skindex-17. J Invest 
Dermatol 126:1244–50
We would be interested in receiving other 
HSR-related papers, such as those regarding 
pharmacoeconomic studies, as well.
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